Table 3.
COVID-19 mRNA liposomal vaccine in the clinical trial.
| Name | Company | Location | Phase | |
|---|---|---|---|---|
| 1 | mRNA-1273 | Moderna | America | Phase Ⅲ NCT04470427 |
| 2 | BNT 162b2 | BioNTech | Germany | Phase Ⅲ NCT04368728 |
| 3 | CVnCoV | CureVac AG | Germany | Phase Ⅲ NCT04674189 |
| 4 | ARCoV | Abogen | China | Phase Ⅱ ChiCTR2000039212 |
| 5 | ARCT-021 | Arcturus | America | Phase Ⅱ NCT04668339 |
| 6 | LNP-nCoVsaRNA | Imperial College London | England | Phase Ⅰ SRCTN17072692 |
| 7 | ChulaCoV19 mRNA vaccine | Chulalongkom University | Thailand | Phase Ⅱ NCT05231369 |
Administration route: all intramuscular
Details may be found at the website in the supplementary material